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CPASPathway-based analysis approaches provide additional insights into the pathogenesis of complex
diseases. Copy number variations (CNVs) play an important role in gene expression regulation. Joint path-
way analysis of CNVs and gene expression data should provide more useful information for revealing the
molecular mechanism of complex diseases. To implement trans-omics pathway analysis of genome-wide
CNVs and mRNA expression proﬁles data, we extended the gene set enrichment analysis algorithm and
developed a ﬂexible trans-omics pathway analysis tool CPAS. CPAS was developed by C to interface with
R for efﬁcient data analysis. CNV-gene and pathway-gene annotation ﬁles derived from public database
were included in CPAS. We hope that CPAS could help to identify disease-relevant biological pathways
that were undetectable using traditional single-omic analysis approaches.
 2014 Elsevier Inc. All rights reserved.1. Introduction
Copy number variations (CNVs) are common genomic variabil-
ity in human genome [1]. Through altering gene dosage or genome
organization, CNVs were suggested to explain more than 20% of
gene expression variations [2]. Using genome-wide association
studies of CNVs (GASC), a group of susceptibility loci has been
identiﬁed for complex diseases [3,4]. However, GASC generally
focus on the CNVs with the most signiﬁcant association signals.
Due to multiple testing problems, the susceptibility loci with mod-
erate and weak phenotypic effects are difﬁcult to be detected using
GASC. The susceptibility loci identiﬁed by GASC are limited and
mostly functionally independent. Because individual gene can par-
ticipate in multiple cellular processes, identifying a couple of genes
affecting disease risks is often inadequate for revealing the patho-
genesis of complex diseases.
Gene mRNA expression proﬁle analysis is a useful tool for path-
ogenetic studies of complex diseases. To overcome the limitations
of traditional single gene expression analysis, Subramanian et al.,
proposed gene set-based expression proﬁle analysis and developed
gene set enrichment analysis (GSEA) software [5,6]. Because of
integrating the mRNA expression levels and prior information of
biological functions of multiple genes, GSEA is able to identifydisease relevant biological pathways that are undetectable for sin-
gle gene expression analysis [5]. Inspired by RNA-level GSEA, Wang
et al., proposed genome-wide pathway-based association studies
(PAS) using DNA-level SNP (single nucleotide polymorphism) data
[7], which were successfully applied in the pathogenetic studies of
complex diseases [8,9].
Recently, trans-omics analysis of biological data becomes more
and more popular in pathogenetic studies [10,11]. Because of inte-
grating the information of multiple levels biological data (for
example DNA-level and RNA-level data), trans-omics analysis can
provide more useful information for pathogenetic studies. For
example, Smith et al. successfully integrated DNA-methylation
data into the mRNA expression analysis of glioblastoma, illustrat-
ing the performance of trans-omics mRNA expression analysis
[11]. As common genetic polymorphism markers, CNVs can also
be used for PAS. Given the important role of CNVs in gene expres-
sion regulation, trans-omics joint pathway analysis of CNVs and
mRNA expression proﬁle data should provide more pathogenetic
information. However, the GSEA software was developed for gene
expression proﬁle data and cannot analyze CNVs data. The GSEA-
SNP, SRT and SSEA tools were developed for pathway analysis of
SNP data, and were not able to be directly used for trans-omics
joint pathway analysis of CNVs and mRNA expression proﬁle data.
In this study, we extended the GSEA algorithm and developed a
trans-omics pathway analysis tool, which was named CPAS. CPAS
is capable of identifying disease relevant biological pathways
through joint pathway analysis of genome-wide CNVs and mRNA
expression proﬁle data.
Fig. 1. Scheme of the steps performed by CPAS.
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CPAS is based on the enrichment statistical algorithm of GSEA
[5,6]. To implement trans-omics pathway analysis of genome-wide
CNVs and mRNA expression proﬁle data, we modiﬁed GSEA algo-
rithm. For a given pathway P, let ESPc and ES
P
m denote the enrich-
ment scores (ES) of CNVs and gene expression proﬁle data of
pathway P, respectively. ESPc and ES
P
m are ﬁrst calculated by
weighted Kolmogorov–Smirnov-like running sum statistic using
the statistical analysis results of CNVs and gene expression proﬁle
data [7]. Permutations are then conducted to obtain the null distri-
butions of ESPc and ES
P
m, through randomly shufﬂing the gene labels
of CNVs and gene expression proﬁle data. Normalized enrichment
score (NES) of observed CNVs and gene expression proﬁle data are
calculated as
NESPob ¼
ESPc meanðESPcnullÞ
SDðESPcnullÞ
wc þ ES
P
m meanðESPmnullÞ
SDðESPmnullÞ
ð1:0wcÞ
where wc is the weight parameter of CNVs data. By default, equal
weights ðwc ¼ 0:5Þ are given to CNVs and gene expression data in
CPAS. ESPcnull and ES
P
mnull denote the null distributions of ES
P
c and
ESPm, and are calculated from the permutated CNVs and gene expres-
sion proﬁle data. Following Wang et al.’ approach [7], statistical P
value and false discovery rate are calculated from the permutation.
Detailed analysis algorithm and procedures can be ﬁnd in the doc-
ument of CPAS (Fig. 1).
We developed a program CPAS to implement the approach
proposed by this study. CNV-gene and pathway-gene annotation
information ﬁles are included in CPAS tool. CNV-gene annotation
ﬁle contains 176,058 entries, which are derived from the Database
of Genomic Variants (http://dgv.tcag.ca/dgv/app/home). Two
pathway-gene catalog information ﬁles are available in CPAS
tool. The ﬁrst one contains 3272 pathways or gene ontology catego-
ries, which are derived from the Molecular Signatures Database of
GSEA (http://www.broadinstitute.org/gsea/msigdb/index.jsp). The
second one contains 963 pathways, which are collected from
four public pathway annotation database, including KEGG
(http://www.genome.ad.jp/kegg/pathway.html), BioCarta (http://
www.biocarta.com/genes), Ambion GeneAssist Pathway Atlas
(http://www.ambion.com/tools/pathway) and Gene Ontology
(GO) (http://www.geneontology.org). Users’ annotation ﬁles are
also acceptable in CPAS tool. CPAS was developed by C to interface
with R (http://www.r-project.org/) for efﬁcient data analysis. CPAS
program, documents and illustrative examples are available at
https://sourceforge.net/projects/ cpasv1/ﬁles/.
3. Illustration and results
Two real gene expression proﬁle datasets of Kashin–Beck dis-
ease (KBD) were used to illustrate the application of CPAS [12].
In the ﬁrst dataset, articular cartilage specimens were collected
from 5 KBD patients and 5 healthy subjects, matched for age and
sex. Genetic cartilage diseases, primary osteoarthritis and rheuma-
toid arthritis were excluded by cartilage section examination with
H&E staining. Total RNA was isolated from cartilage specimens.
Microarray hybridization was performed using Agilent Human 1A
22k Whole Genome microarray (containing 21,073 human genes).
GSEA was used to conduct pathway expression analysis of KBD
microarray data. We found that REACTOME_INTRINSIC_PATH-
WAY_FOR_APOPTOSIS (P value < 103) pathway was signiﬁcantly
abnormally expressed in KBD articular cartilage [12]. Within REAC-
TOME_INTRINSIC_PATHWAY_ FOR_APOPTOSIS pathway, 6 genes
showed signiﬁcant expression difference (ratios < 0.5 or ratios >
2.0) between KBD articular cartilage and healthy articular cartilage
[12]. Without loss of generality, the CNVs association testingstatistics of the 6 differently expressed genes were randomly gen-
erated with P values < 0.05 using the ‘‘runif’’ function of R (http://
www.r-project.org/). The CNVs association testing statistics of
remaining genes in microarray were randomly generated with P
values ranging from 0.0 to 1.0. Among the 3272 pathways or gene
ontology categories analyzed by this study, CPAS detected the most
signiﬁcant association between KBD and REACTOME_INTRIN-
SIC_PATHWAY_FOR_APOPTOSIS (FDR = 0.003) (Fig. 2A). Excessive
chondrocyte apoptosis is one of the primary cartilage damage of
KBD [13–15]. Wang et al. found that the percentage of apoptotic
chondrocytes (33.60%) in KBD articular cartilage was much bigger
than that (1.33%) in healthy articular cartilage [15]. Dysfunction of
apoptosis related REACTOME_INTRINSIC_PATHWAY_FOR_APOP-
TOSIS pathway may contribute to the articular cartilage damage
of KBD.
In the second dataset, total RNA was isolated from isolated from
peripheral blood mononuclear cells of 20 KBD patients and 12
healthy controls. Microarray hybridization was performed using
Agilent Human 1A 22k Whole Genome microarray. GSEA was
applied for pathway expression analysis. We found that REACTOM-
E_MAPK_TARGETS_NUCLEAR_EVENTS_MEDIATED_BY_MAP_KINASES
(P value < 103) pathwaywas signiﬁcantly abnormally expressed in
KBD peripheral blood mononuclear cells [12]. Without loss of gen-
erality, the CNVs association testing statistics of 3 differently
expressed genes in the REACTOME_MAPK_TARGETS_NUCLEAR_EVENTS_
MEDIATED_BY_MAP_KINASES pathway were randomly generated
Fig. 2. Plot of CPAS pathway analysis results of KBD. The Y-axis shows –log10 (FDR) of the 963 pathways analyzed by CPAS.
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project.org/). The CNVs association testing statistics of remaining
genes in microarray were randomly generated with P values rang-
ing from 0.0 to 1.0. Among the 3272 pathways or gene ontology cat-
egories analyzed by this study, CPAS detected the most signiﬁcant
association between KBD and REACTOME_MAPK_TARGETS_
NUCLEAR_EVENTS_ MEDIATED_BY_MAP_KINASES (FDR = 0.017)
(Fig. 2B). The REACTOME_MAPK_TARGETS_NUCLEAR_EVENTS_
MEDIATED_BY_MAP_KINASES pathway consists of genes involved
in mitogen-activated protein kinases (MAPK)-medicated biological
process, such as cell differentiation, apoptosis and inﬂammation. It
has been demonstrated that MAPK played an important role in the
regulation of chondrogenesis and cartilage development [16]. Dys-
function of MAPK contributed to cartilage-related diseases, such as
osteoarthritis [16]. REACTOME_MAPK_TARGETS_NUCLEAR_EVENTS_
MEDIATED_BY_MAP_KINASES pathway may also involve in the
development of KBD.4. Discussion
Through identifying abnormally expressed genes in target dis-
eases, gene expression proﬁle studies can provide insight into the
pathogenesis of complex diseases. Because traditional single gene
expression analysis evaluates individually the expression level of
each gene without considering intergenic functional relationships,
it usually provides limited information for understanding the path-
ogenesis of complex diseases. To address this issue, GSEA was pro-
posed for identifying abnormally expressed biological pathways in
target diseases [5,6]. Because the biological function of most path-
ways were known, identifying disease relevant pathways can pro-
vide more useful information for pathogenetic studies and drug
development. Recently, trans-omics analysis of multi-omics bio-
logical data becomes more and more popular [10,11]. However,
current GSEA software (http://www.broadinstitute.org/gsea/
index.jsp) cannot be applied for trans-omics pathway analysis.
Inspired by GSEA, we extended the statistical analysis algorithm
of GSEA to joint pathway analysis of genome-wide CNVs and
mRNA expression proﬁle data. With the modiﬁed GSEA algorithm,
CPAS can help to identify disease-relevant biological pathways
through jointly analyzing genome-wide DNA-level CNVs and
mRNA expression proﬁle data. Because CNVs play an important
role in gene expression regulation [2], it is reasonable to infer that
integrating CNVs information into mRNA-level pathway expres-
sion analysis provided more pathogenetic information for complex
diseases. Additionally, because of using pathways as the units ofstatistical analysis, the loss of power caused by multiple testing
problems is largely reduced in CPAS.
In summary, we extended GSEA algorithm and developed a
ﬂexible tool for trans-omics pathway analysis of genome-wide
CNVs and gene expression proﬁle data. CPAS may help to identify
disease-relevant biological pathways that are undetectable using
traditional single gene or single-omic analysis approaches.Funding
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